NASDAQ:ITCI - Intra-Cellular Therapies Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $47.43
Forecasted Upside: 8.76 %
Number of Analysts: 7
Breakdown:
0 Sell Ratings
0 Hold Ratings
7 Buy Ratings
0 Strong Buy Ratings

^$43.61 As of 06/21/2021 04:15 PM ET

▲ +0.43 (1.00%)

1 month | 3 months | 12 months

Get New Intra-Cellular Therapies Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for ITCI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ITCI

^$47.43

▲ +8.76% Upside Potential

This price target is based on 7 analysts offering 12 month price targets for Intra-Cellular Therapies in the last 3 months. The average price target is $47.43, with a high forecast of $70.00 and a low forecast of $36.00. The average price target represents a 8.76% upside from the last price of $43.61.

Read Analyst Price Chart Description

Current Consensus is Buy

The current consensus among 7 polled investment analysts is to buy stock in Intra-Cellular Therapies. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
8 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/29/2019

0 strong buy ratings
9 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

3/28/2020

0 strong buy ratings
9 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

6/26/2020

0 strong buy ratings
5 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

9/24/2020

0 strong buy ratings
8 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

12/23/2020

0 strong buy ratings
7 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/23/2021

0 strong buy ratings
7 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/22/2021

0 strong buy ratings
7 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/21/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
12/29/2020	Cantor Fitzgerald	Boost Price Target	Overweight	$53.00 ➝ $54.00	N/A
12/15/2020	Bank of America	Initiated Coverage	Buy	$40.00	High
12/10/2020	The Goldman Sachs Group	Initiated Coverage	Buy	$38.00	High
11/2/2020	Royal Bank of Canada	Lower Price Target	Outperform	$43.00 ➝ $36.00	High
11/2/2020	BTIG Research	Lower Price Target	Buy	$80.00 ➝ $40.00	High
10/5/2020	Canaccord Genuity	Reiterated Rating	Buy		High
9/10/2020	Royal Bank of Canada	Boost Price Target		$33.00 ➝ $43.00	High
9/9/2020	BTIG Research	Boost Price Target		$68.00 ➝ $80.00	Low
9/9/2020	JMP Securities	Boost Price Target	Outperform	$47.00 ➝ $54.00	N/A
8/11/2020	Canaccord Genuity	Reiterated Rating	Buy	$70.00	Low
3/3/2020	BTIG Research	Lower Price Target	Buy	$73.00 ➝ $68.00	Medium
3/3/2020	Canaccord Genuity	Reiterated Rating	Buy		Medium
2/19/2020	Evercore ISI	Initiated Coverage	Outperform		Medium
2/18/2020	Cantor Fitzgerald	Reiterated Rating	Overweight	$43.00 ➝ $47.00	High
1/31/2020	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$19.00 ➝ $26.00	Low
12/23/2019	Canaccord Genuity	Boost Price Target	Buy	$29.00 ➝ $65.00	High
12/23/2019	BTIG Research	Boost Price Target	Buy	$34.00 ➝ $73.00	High
9/10/2019	SVB Leerink	Reiterated Rating	Buy		Low
9/10/2019	JMP Securities	Set Price Target	Buy	$21.00	N/A
9/10/2019	Cantor Fitzgerald	Set Price Target	Buy	$27.00	N/A
8/12/2019	Jefferies Financial Group	Initiated Coverage	Buy ➝ Buy	$16.00 ➝ $16.00	Low
8/8/2019	JMP Securities	Lower Price Target	Market Outperform	$24.00 ➝ $21.00	High
8/7/2019	Royal Bank of Canada	Set Price Target	Buy	$26.00	Low
7/8/2019	Cowen	Reiterated Rating	Buy	$28.00	High
5/23/2019	Cantor Fitzgerald	Reiterated Rating	Overweight	$26.00 ➝ $29.00	Medium
5/8/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$26.00	High
4/15/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$26.00	Medium
12/12/2018	Royal Bank of Canada	Boost Price Target	Outperform	$35.00 ➝ $37.00	Low
12/12/2018	Canaccord Genuity	Set Price Target	Buy	$31.00	Low
12/11/2018	Cantor Fitzgerald	Set Price Target	Buy	$32.00	High
11/13/2018	SVB Leerink	Initiated Coverage	Outperform	$27.00	Medium
11/7/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$32.00	Low
10/23/2018	Cantor Fitzgerald	Set Price Target	Buy	$32.00	Low
10/19/2018	SVB Leerink	Reiterated Rating	Outperform		High
10/4/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$32.00	High
8/23/2018	Cantor Fitzgerald	Initiated Coverage	Overweight	$32.00	High
8/3/2018	Royal Bank of Canada	Reiterated Rating	Buy	$35.00	High
8/2/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$28.00	High
8/2/2018	Canaccord Genuity	Set Price Target	Buy	$31.00	Low
7/23/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$28.00	Low
6/6/2018	Canaccord Genuity	Set Price Target	Buy	$31.00	High
4/3/2018	SVB Leerink	Set Price Target	Buy	$25.00	High
4/2/2018	Canaccord Genuity	Set Price Target	Buy	$31.00	Low
3/13/2018	Canaccord Genuity	Set Price Target	Buy	$31.00	Medium
3/4/2018	SVB Leerink	Reiterated Rating	Outperform		Low
3/2/2018	SunTrust Banks	Reiterated Rating	Buy	$28.00	Low
3/2/2018	Cowen	Reiterated Rating	Buy	$28.00	High
3/1/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$28.00	High
2/26/2018	JPMorgan Chase & Co.	Initiated Coverage	Overweight ➝ Overweight	$25.00	High
2/8/2018	Royal Bank of Canada	Initiated Coverage	Outperform ➝ Outperform	$33.00	Medium
12/15/2017	Canaccord Genuity	Initiated Coverage	Buy ➝ Buy	$31.00	High
11/8/2017	SunTrust Banks	Upgrade	Hold ➝ Buy		N/A
9/8/2017	BTIG Research	Reiterated Rating	Buy	$36.00	Medium
9/8/2017	SunTrust Banks	Reiterated Rating	Hold	$16.00 ➝ $22.00	Low
9/8/2017	Cowen	Reiterated Rating	Outperform	$20.00 ➝ $27.00	Medium
9/7/2017	Piper Jaffray Companies	Upgrade	Neutral ➝ Overweight	$14.00 ➝ $33.00	High
8/24/2017	Piper Jaffray Companies	Set Price Target	Hold	$14.00	Medium
8/24/2017	JMP Securities	Upgrade	Market Perform ➝ Outperform	$24.00	High
8/23/2017	Cowen	Reiterated Rating	Buy	$20.00	High
8/23/2017	SVB Leerink	Upgrade	Market Perform ➝ Outperform		High
8/15/2017	SVB Leerink	Reiterated Rating	Market Perform	$12.00	Low
8/10/2017	Piper Jaffray Companies	Set Price Target	Hold	$10.00	High
8/9/2017	Cantor Fitzgerald	Reiterated Rating	Buy		High
5/11/2017	Cantor Fitzgerald	Set Price Target	Buy	$29.00	Low
5/2/2017	Cantor Fitzgerald	Lower Price Target	Overweight	$32.00 ➝ $29.00	Medium
5/2/2017	LADENBURG THALM/SH SH	Downgrade	Buy ➝ Neutral		High
5/2/2017	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$29.00 ➝ $10.00	High
5/1/2017	Piper Jaffray Companies	Downgrade	Overweight ➝ Neutral	$22.00 ➝ $10.00	High
3/20/2017	SVB Leerink	Reiterated Rating	Outperform		Low
3/2/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$32.00	N/A
3/1/2017	Cowen	Reiterated Rating	Buy		N/A
2/23/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$22.00	N/A
12/22/2016	BTIG Research	Initiated Coverage	Buy	$44.00	N/A
12/16/2016	Cantor Fitzgerald	Initiated Coverage	Overweight	$32.00	N/A
11/9/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$22.00	N/A
11/1/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$22.00	N/A
10/10/2016	Piper Jaffray Companies	Set Price Target	Buy	$22.00	N/A
9/30/2016	Royal Bank of Canada	Reiterated Rating	Outperform	$74.00 ➝ $49.00	N/A
9/30/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$57.00 ➝ $22.00	N/A
9/30/2016	SVB Leerink	Reiterated Rating	Outperform	$95.00 ➝ $29.00	N/A
9/29/2016	JMP Securities	Downgrade	Outperform ➝ Market Perform		N/A
9/29/2016	Royal Bank of Canada	Lower Price Target	Outperform	$74.00 ➝ $49.00	N/A
9/29/2016	SunTrust Banks	Downgrade	Buy ➝ Neutral	$60.00 ➝ $15.00	N/A
9/13/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$57.00	N/A
8/11/2016	SVB Leerink	Reiterated Rating	Buy	$95.00	N/A
8/5/2016	Cowen	Reiterated Rating	Buy	$75.00	N/A
6/30/2016	SVB Leerink	Reiterated Rating	Buy		N/A
6/29/2016	Cowen	Reiterated Rating	Buy		N/A
6/22/2016	SVB Leerink	Reiterated Rating	Buy		N/A
6/22/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$57.00	N/A

(Data available from 6/21/2016 forward)

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also developing lumateperone, which is in Phase 3 clinical trials for the treatment of bipolar depression, as well as to treat autism spectrum disorder, and sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for the treatment of Parkinson's disease and heart failure; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.

Today's Range

Now: $43.61

$43.03

$43.83

50 Day Range

MA: $36.77

$29.30

$43.33

52 Week Range

Now: $43.61

$17.26

$43.82

Volume

9,973 shs

Average Volume

561,131 shs

Market Capitalization

$3.54 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.33

Frequently Asked Questions

What sell-side analysts currently cover shares of Intra-Cellular Therapies?

The following Wall Street research analysts have issued stock ratings on Intra-Cellular Therapies in the last twelve months: Bank of America Co., BTIG Research, Canaccord Genuity, Cantor Fitzgerald, JMP Securities, Royal Bank of Canada, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for ITCI.

What is the current price target for Intra-Cellular Therapies?

7 Wall Street analysts have set twelve-month price targets for Intra-Cellular Therapies in the last year. Their average twelve-month price target is $47.43, suggesting a possible upside of 8.9%. Canaccord Genuity has the highest price target set, predicting ITCI will reach $70.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $36.00 for Intra-Cellular Therapies in the next year.
View the latest price targets for ITCI.

What is the current consensus analyst rating for Intra-Cellular Therapies?

Intra-Cellular Therapies currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ITCI will outperform the market and that investors should add to their positions of Intra-Cellular Therapies.
View the latest ratings for ITCI.

What other companies compete with Intra-Cellular Therapies?

Other companies that are similar to Intra-Cellular Therapies include Grifols, Dr. Reddy's Laboratories, CureVac, Maravai LifeSciences, Ono Pharmaceutical, Teva Pharmaceutical Industries, Bausch Health Companies, Jazz Pharmaceuticals, BridgeBio Pharma, Arrowhead Pharmaceuticals, Mirati Therapeutics, United Therapeutics, Ascendis Pharma A/S, Evotec and Ultragenyx Pharmaceutical.

How do I contact Intra-Cellular Therapies' investor relations team?

Intra-Cellular Therapies' physical mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company's listed phone number is 646-440-9333 and its investor relations email address is [email protected] The official website for Intra-Cellular Therapies is www.intracellulartherapies.com.